These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

210 related articles for article (PubMed ID: 26735180)

  • 1. NG2 proteoglycan as a pericyte target for anticancer therapy by tumor vessel infarction with retargeted tissue factor.
    Brand C; Schliemann C; Ring J; Kessler T; Bäumer S; Angenendt L; Mantke V; Ross R; Hintelmann H; Spieker T; Wardelmann E; Mesters RM; Berdel WE; Schwöppe C
    Oncotarget; 2016 Feb; 7(6):6774-89. PubMed ID: 26735180
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Vascular infarction by subcutaneous application of tissue factor targeted to tumor vessels with NGR-peptides: activity and toxicity profile.
    Dreischalück J; Schwöppe C; Spieker T; Kessler T; Tiemann K; Liersch R; Schliemann C; Kreuter M; Kolkmeyer A; Hintelmann H; Mesters RM; Berdel WE
    Int J Oncol; 2010 Dec; 37(6):1389-97. PubMed ID: 21042706
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Tissue-factor fusion proteins induce occlusion of tumor vessels.
    Schwöppe C; Kessler T; Persigehl T; Liersch R; Hintelmann H; Dreischalück J; Ring J; Bremer C; Heindel W; Mesters RM; Berdel WE
    Thromb Res; 2010 Apr; 125 Suppl 2():S143-50. PubMed ID: 20433995
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tumor Growth Inhibition via Occlusion of Tumor Vasculature Induced by N-Terminally PEGylated Retargeted Tissue Factor tTF-NGR.
    Brand C; Fröhlich M; Ring J; Schliemann C; Kessler T; Mantke V; König S; Lücke M; Mesters RM; Berdel WE; Schwöppe C
    Mol Pharm; 2015 Oct; 12(10):3749-58. PubMed ID: 26310827
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Low-Energy Ultrasound Treatment Improves Regional Tumor Vessel Infarction by Retargeted Tissue Factor.
    Brand C; Dencks S; Schmitz G; Mühlmeister M; Stypmann J; Ross R; Hintelmann H; Schliemann C; Müller-Tidow C; Mesters RM; Berdel WE; Schwöppe C
    J Ultrasound Med; 2015 Jul; 34(7):1227-36. PubMed ID: 26112625
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Combinatorial effects of doxorubicin and retargeted tissue factor by intratumoral entrapment of doxorubicin and proapoptotic increase of tumor vascular infarction.
    Stucke-Ring J; Ronnacker J; Brand C; Höltke C; Schliemann C; Kessler T; Schmidt LH; Harrach S; Mantke V; Hintelmann H; Hartmann W; Wardelmann E; Lenz G; Wünsch B; Müller-Tidow C; Mesters RM; Schwöppe C; Berdel WE
    Oncotarget; 2016 Dec; 7(50):82458-82472. PubMed ID: 27738341
    [TBL] [Abstract][Full Text] [Related]  

  • 7. NG2 proteoglycan-binding peptides target tumor neovasculature.
    Burg MA; Pasqualini R; Arap W; Ruoslahti E; Stallcup WB
    Cancer Res; 1999 Jun; 59(12):2869-74. PubMed ID: 10383148
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Non-invasive monitoring of tumor-vessel infarction by retargeted truncated tissue factor tTF-NGR using multi-modal imaging.
    Persigehl T; Ring J; Bremer C; Heindel W; Holtmeier R; Stypmann J; Claesener M; Hermann S; Schäfers M; Zerbst C; Schliemann C; Mesters RM; Berdel WE; Schwöppe C
    Angiogenesis; 2014 Jan; 17(1):235-46. PubMed ID: 24136410
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Infarction of tumor vessels by NGR-peptide-directed targeting of tissue factor: experimental results and first-in-man experience.
    Bieker R; Kessler T; Schwöppe C; Padró T; Persigehl T; Bremer C; Dreischalück J; Kolkmeyer A; Heindel W; Mesters RM; Berdel WE
    Blood; 2009 May; 113(20):5019-27. PubMed ID: 19179306
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Anticancer therapy by tumor vessel infarction with polyethylene glycol conjugated retargeted tissue factor.
    Schwöppe C; Zerbst C; Fröhlich M; Schliemann C; Kessler T; Liersch R; Overkamp L; Holtmeier R; Stypmann J; Dreiling A; König S; Höltke C; Lücke M; Müller-Tidow C; Mesters RM; Berdel WE
    J Med Chem; 2013 Mar; 56(6):2337-47. PubMed ID: 23496322
    [TBL] [Abstract][Full Text] [Related]  

  • 11. CD13 as target for tissue factor induced tumor vascular infarction in small cell lung cancer.
    Schmidt LH; Stucke-Ring J; Brand C; Schliemann C; Harrach S; Muley T; Herpel E; Kessler T; Mohr M; Görlich D; Kreuter M; Lenz G; Wardelmann E; Thomas M; Berdel WE; Schwöppe C; Hartmann W
    Lung Cancer; 2017 Nov; 113():121-127. PubMed ID: 29110838
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The NG2 Proteoglycan in Pericyte Biology.
    Stallcup WB
    Adv Exp Med Biol; 2018; 1109():5-19. PubMed ID: 30523586
    [TBL] [Abstract][Full Text] [Related]  

  • 13. NG2 proteoglycan promotes tumor vascularization via integrin-dependent effects on pericyte function.
    You WK; Yotsumoto F; Sakimura K; Adams RH; Stallcup WB
    Angiogenesis; 2014 Jan; 17(1):61-76. PubMed ID: 23925489
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Specific tissue factor delivery using a tumor-homing peptide for inducing tumor infarction.
    Shi Q; Zhang Y; Liu S; Liu G; Xu J; Zhao X; Anderson GJ; Nie G; Li S
    Biochem Pharmacol; 2018 Oct; 156():501-510. PubMed ID: 30222966
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The EGFR inhibitor gefitinib suppresses recruitment of pericytes and bone marrow-derived perivascular cells into tumor vessels.
    Iivanainen E; Lauttia S; Zhang N; Tvorogov D; Kulmala J; Grenman R; Salven P; Elenius K
    Microvasc Res; 2009 Dec; 78(3):278-85. PubMed ID: 19596357
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Early vascular deficits are correlated with delayed mammary tumorigenesis in the MMTV-PyMT transgenic mouse following genetic ablation of the NG2 proteoglycan.
    Gibby K; You WK; Kadoya K; Helgadottir H; Young LJ; Ellies LG; Chang Y; Cardiff RD; Stallcup WB
    Breast Cancer Res; 2012 Apr; 14(2):R67. PubMed ID: 22531600
    [TBL] [Abstract][Full Text] [Related]  

  • 17. NG2 Proteoglycan-Dependent Contributions of Pericytes and Macrophages to Brain Tumor Vascularization and Progression.
    Stallcup WB; You WK; Kucharova K; Cejudo-Martin P; Yotsumoto F
    Microcirculation; 2016 Feb; 23(2):122-33. PubMed ID: 26465118
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Generation of fusion proteins for selective occlusion of tumor vessels.
    Kessler T; Schwöppe C; Liersch R; Schliemann C; Hintelmann H; Bieker R; Berdel WE; Mesters RM
    Curr Drug Discov Technol; 2008 Mar; 5(1):1-8. PubMed ID: 18537561
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Targeting pericytes diminishes neovascularization in orthotopic uveal melanoma in nerve/glial antigen 2 proteoglycan knockout mouse.
    Ozerdem U
    Ophthalmic Res; 2006; 38(5):251-4. PubMed ID: 16888406
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The glial precursor proteoglycan, NG2, is expressed on tumour neovasculature by vascular pericytes in human malignant brain tumours.
    Chekenya M; Enger PØ; Thorsen F; Tysnes BB; Al-Sarraj S; Read TA; Furmanek T; Mahesparan R; Levine JM; Butt AM; Pilkington GJ; Bjerkvig R
    Neuropathol Appl Neurobiol; 2002 Oct; 28(5):367-80. PubMed ID: 12366818
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.